Publications by authors named "M Ravnborg"
Background: Patient-reported outcomes (PROs) are increasingly being used as outcomes in secondary progressive multiple sclerosis (SPMS) trials. We examined how PROs reflect disease burden in SPMS.
Methods: In this observational prospective study, 65 SPMS patients were examined by five different PROs (Fatigue Scale Motor Cognition (FSMC), Multiple Sclerosis Impact Scale version 2 (MSIS-29v2), 36-Item Short Form Health Survey version 2 (SF-36v2), EQ-5D-5L and Work Productivity and Activity Impairment Questionnaire: Multiple Sclerosis version 2.
Article Synopsis
- The study investigates the relationship between the Multiple Sclerosis Impairment Scale (MSIS) and other measures like the Expanded Disability Status Scale (EDSS) and MRI outcomes in patients with secondary progressive MS (SPMS).
- A total of 68 SPMS patients were assessed, revealing significant correlations between MSIS and functional mobility tests, suggesting that MSIS is a relevant tool for evaluating impairment.
- Findings indicate that MSIS may be more sensitive in detecting cerebellar and sensory function impairments compared to EDSS, as it showed stronger correlations with MRI markers of brain atrophy.
Objectives: In a prospective phase IV trial of the first-line oral treatment dimethyl fumarate (DMF), we examined dynamics of neurofilament light (NFL) chain in serum, plasma and cerebrospinal fluid (CSF) samples collected over 12 months from relapsing-remitting multiple sclerosis (RRMS) patients. NFL changes were related to disease activity.
Methods: We examined NFL levels by single-molecule array in 88 CSF, 348 plasma and 131 sera from treatment-naïve RRMS patients (n=52), healthy controls (n=23) and a placebo group matched by age, sex and NFL (n=52).
Background: Disease-modifying therapies (DMT) are increasingly used for children with multiple sclerosis (MS) even though most double-blinded randomized controlled trials evaluating efficacy, safety and dosing strategy of a specific drug have included adults.
Objective: To investigate predictors of treatment outcomes in patients with paediatric onset MS treated with DMTs.
Methods: Prospective cohort study from the nationwide Danish Multiple Sclerosis Registry including all patients with a MS diagnosis who initiated treatment with an approved DMT before the age of 18 ( = 137) and followed until their 25th birthday.
Background: More than half of all patients with multiple sclerosis (MS) acquire cognitive impairment as part of their disease progression. Because cognitive dysfunction adds substantially to disability and coping strategies, a cost-effective screening tool is needed for cognitive impairment. The Multiple Sclerosis Neuropsychological Screening Questionnaire (MSNQ) has previously shown good validity in American, Argentinean, and Dutch MS cohorts.
View Article and Find Full Text PDF